Genhouse Bio completes crossover financing round exceeding 300 million

On January 13, Genhouse Bio, a research-driven enterprise dedicated to developing global next-generation anti-tumor small-molecule drugs through an integrated technology platform, announced the completion of a crossover financing round exceeding 300 million. This round was led by Green Pine Capital Partners, with participation from multiple institutions including Linzhuo Investment, Yuanbio Venture Capital, Guangzhou Industry Investment, VIVATEC, Bohe Fund, and Guoju Investment. Previously, Legend Star had invested in Genhouse Bio's Series A and Series B rounds.

As a biotech company driven by independent innovation, Genhouse Bio remains focused on developing globally leading targeted anti-tumor small-molecule therapeutics. Genhouse Bio has established a drug development philosophy centered on "AI/Biology-Driven Smart Design," deeply integrating computational chemistry, artificial intelligence, and internal experimental platforms to form an efficient R&D system characterized by "data-driven, rapid iteration." This system comprehensively empowers the entire process from drug discovery to clinical development.

Genhouse Bio has built a differentiated pipeline covering the Ras signaling pathway and synthetic lethality, advancing several globally leading programs into clinical stages. This demonstrates Genhouse Bio's capability for sustained innovation and positions it to provide internationally competitive solutions for precision and combination therapies targeting refractory tumors.

Leveraging its platform innovation capabilities and pipeline potential, Genhouse Bio has successively received recognition such as the "Gusu Major Innovation Team" and "Jiangsu Major Special Project," and has participated in the "National Major Scientific and Technological Special Project for Innovative Drug R&D." Its technological approach and innovative value have been acknowledged by multiple stakeholders.

The completion of this financing will further accelerate Genhouse Bio's R&D progress and strategic expansion. Moving forward, Genhouse Bio will rely on its AI-enabled efficient innovation system, focus on unmet clinical needs, collaborate with academia, industry, and research institutions, and continue to advance the development of globally competitive innovative drugs, aiming to deliver breakthrough therapeutic solutions for patients.